Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
April 25, 2022 07:33 ET
|
Ocugen
MALVERN, Pa., April 25, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and...
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
April 01, 2022 07:37 ET
|
Ocugen
MALVERN, Pa., April 01, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and...
Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results
February 25, 2022 07:31 ET
|
Ocugen
U.S. FDA lifts clinical hold on IND application for COVAXIN™ (BBV152), clearing the pathway for Phase 2/3 clinical trial in support of a BLA submissionEngagement with U.S. FDA to advance pediatric EUA...
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
December 16, 2021 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
December 09, 2021 07:28 ET
|
Ocugen
Gene therapy candidate has potential to address a large number of retinitis pigmentosa and Leber congenital amaurosis gene mutations with a single productTrial to start in Q1 2022 will enroll patients...
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome
March 17, 2021 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Third Quarter 2020 Operating and Financial Results
November 16, 2020 07:00 ET
|
ProQR Therapeutics N.V.
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021Enrollment completed for QR-421a...
ProQR Announces Second Quarter 2020 Operating and Financial Results
August 06, 2020 16:30 ET
|
ProQR Therapeutics N.V.
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;Strategic...
Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease
July 27, 2020 07:30 ET
|
Ocugen
MALVERN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
March 31, 2020 06:00 ET
|
ProQR Therapeutics N.V.
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse...